Daily Digest — October 8, 2026

Just Filed

Centinel Spine Holdco (CNTL) — Orthopedic Implants

CNTL · Initial S-1 · terms not yet set

What it does: Total disc replacement (TDR) implants — the prodisc platform substitutes a damaged spinal disc with an articulating prosthetic rather than fusing adjacent vertebrae into a rigid block. Scale: $132.2 million in FY revenue · 80% gross margin · 1,500 active surgeons · 35 countries Balance sheet flag: Total debt obligations that materially exceed the $20.0 million in cash on hand · accumulated deficit $188.4 million

---

The prodisc platform has been in commercial use for 35 years and has been implanted more than 300,000 times worldwide, backed by 590 peer-reviewed papers and 60 long-term follow-up studies. That clinical depth is unusual at this revenue scale, and it matters: TDR is a Class III device category where outcomes data is the moat.

Operating trajectory. Revenue reached $132.2 million in the most recent fiscal year, up 39% from $95.1 million the year prior. The first half of 2026 extended the pace — $85.2 million in H1, growing 42% year-over-year. Gross margins hold at 80%. Adjusted EBITDA improved 241% year-over-year to $20.2 million for the full year, and the company posted net income of $10.2 million in H1 2026, a meaningful shift from a $500,000 net loss in the same period a year earlier.

Balance sheet. The operating improvement doesn't change the debt picture. The company carries a term loan outstanding at $61.4 million, a 2023 credit agreement at $12.5 million outstanding, a 6.0% convertible note at $10.1 million, and 4.00% convertible notes at $46.0 million in principal plus $6.9 million in accrued interest — against $20.0 million in cash. Two structural features filter the economics further: the 4.00% notes convert at IPO at a 30% discount to the offering price (dilutive to public buyers at pricing), and the Up-C tax receivable agreement routes 85% of future tax savings to pre-IPO equity holders.

Market and clinical case. The U.S. TDR market is estimated at $2.5 billion, growing at a 7.7% CAGR versus 0.6% for traditional fusion — the market it displaces. Of roughly 750,000 annual instrumented fusion procedures in the U.S., the filing estimates 275,000 are addressable by TDR, yet only about 58,000 TDR procedures are currently performed each year. The clinical data cited is notable: a 48% reduction in reoperation risk, a 4x reduction in adjacent-level interventions, and a revision rate of just 1% over 7–21 year follow-up in the prodisc L.

Watch items. Two voluntary product recalls are disclosed — one in December 2025 affecting 6 implanted patients, another in March 2026 covering a lot of 30 units with 7 implanted. Small in scope, but in a Class III device business, recall history is part of the regulatory profile. Single-source suppliers for key components carry a 24-month qualification timeline, limiting supply-chain flexibility.

The clinical platform appears strong; the offering is best understood as a recapitalization wearing a growth story's clothes. How much of the improving operating economics remain available to public shareholders — after the conversion discount, the TRA, and the debt the proceeds will likely retire — is the question worth tracking as terms are set.